Recent advances in the development of tissue transglutaminase (TG2) inhibitors

Research output: Contribution to journalArticle

View graph of relations Save citation



Research units


Tissue transglutaminase (TG2) is a Ca2+-dependent enzyme and probably the most ubiquitously expressed member of the mammalian transglutaminase family. TG2 plays a number of important roles in a variety of biological processes. Via its transamidating function, it is responsible for the cross-linking of proteins by forming isopeptide bonds between glutamine and lysine residues. Intracellularly, Ca2+ activation of the enzyme is normally tightly regulated by the binding of GTP. However, upregulated levels of TG2 are associated with many disease states like celiac sprue, certain types of cancer, fibrosis, cystic fibrosis, multiple sclerosis, Alzheimer's, Huntington's and Parkinson's disease. Selective inhibitors for TG2 both cell penetrating and non-cell penetrating would therefore serve as novel therapeutic tools for the treatment of these disease states. Moreover, they would provide useful tools to fully elucidate the cellular mechanisms TG2 is involved in and help comprehend how the enzyme is regulated at the cellular level. The current paper is intended to give an update on the recently discovered classes of TG2 inhibitors along with their structure-activity relationships. The biological properties of these derivatives, in terms of both activity and selectivity, will also be reported in order to translate their potential for future therapeutic developments. © 2011 Springer-Verlag.



Original languageEnglish
Pages (from-to)119-127
Number of pages9
JournalAmino Acids
Issue number1
Early online date13 Dec 2011
Publication statusPublished - Jan 2013


  • inhibitors, structure-activity relationships (SAR), TG2, tissue transglutaminase

Download statistics

No data available

Employable Graduates; Exploitable Research

Copy the text from this field...